New test paves the way for tailored treatment of deadliest form of ovarian cancer
A new tool will help researchers and clinicians to classify ovarian cancer patients’ tumours into…
Browsing: ovarian cancer
New Approach to Ovarian Cancer Treatment
Overall survival from ovarian cancer has not improved for several decades. Now, a Peter Mac-led…
Study confirms important clues to fight ovarian cancer
The rogue cellular engine that drives a majority of ovarian cancers remains frustratingly difficult to…
Personalised ovarian cancer risk prediction reduces worries
Offering personalised ovarian cancer risk prediction to women shows that 98 per cent of participants…
Funding to boost research into new therapy combinations for ovarian cancer
Peter Mac researchers have been awarded a four year grant from the Federal Government’s Medical…
ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation
Maintenance therapy with olaparib extended overall survival by nearly 13 months (12.9) compared with placebo…
FDA approves niraparib for first-line maintenance of advanced ovarian cancer
The Food and Drug Administration (FDA) approved niraparib for the maintenance treatment of adult patients…
Drug overcomes chemotherapy resistance in ovarian cancer
An international research team, led by scientists from Mater Research—The University of Queensland, have discovered…
Breastfeeding linked to lower ovarian cancer risk
An international study involving researchers from QIMR Berghofer Medical Research Institute has found women who…
New research shows which ovarian cancer patients won’t benefit from immune-PARP combo
In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors…